Efficacy and Safety of Neoadjuvant Immunotherapy plus Chemotherapy versus Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer Treatment: A Mixed Method Meta-Analysis Based on Global Randomized Controlled Trials

Abstract

This study explores the efficacy and safety of combining immunotherapy with chemotherapy for neoadjuvant non-small cell lung cancer (NSCLC) treatment. Despite the rapid advancement of immunotherapy, direct evidence comparing it with chemotherapy alone is limited. Following PRISMA guidelines, we analyzed global phase II and III randomized controlled trials data. Our meta-analysis included nine trials with 3431 participants, showing that combined treatment significantly improved event-free survival, pathological complete response, major pathological response, surgical acceptance, and R0 resection rates in NSCLC compared with chemotherapy alone. Safety analysis revealed similar all adverse event incidences between treatments, while Grade ≥3 adverse events were higher than those in neoadjuvant chemotherapy. Network meta-analysis confirmed the benefits of different immunotherapeutic drugs and efficacy in different subgroups. The study's high-quality evidence suggests that neoadjuvant immunotherapy plus chemotherapy should be considered in clinical practice for NSCLC, with further research needed to optimize treatment strategies and improve patient outcomes.

Keywords

efficacy / immunotherapy / neoadjuvant therapy / non-small cell lung cancer / safety

References

[1] R. L. Siegel, A. N. Giaquinto, and A. Jemal, “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74, no. 1 (2024): 12-49.

[2] J. Ji, C. Zhang, L. Peng, and W. Jiao, “Research Progress, Benefit Groups, Treatment Cycle and Efficacy Prediction of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer,” Zhongguo Fei Ai Za Zhi 25, no. 2 (2022): 92-101.

[3] H. M. Pinedo and G. Giaccone, “Chemotherapy,” The Lancet 349 (1997): S7-S9.

[4] G. L. Szeto and S. D. Finley, “Integrative Approaches to Cancer Immunotherapy,” Trends in Cancer 5, no. 7 (2019): 400-410.

[5] P. M. Forde, J. E. Chaft, K. N. Smith, et al., “Neoadjuvant PD-1 Blockade in Resectable Lung Cancer,” New England Journal of Medicine 378, no. 21 (2018): 1976-1986.

[6] S. Gao, N. Li, S. Gao, et al., “Neoadjuvant PD-1 Inhibitor (Sintilimab) in NSCLC,” Journal of Thoracic Oncology 15, no. 5 (2020): 816-826.

[7] D. Rodríguez-Abreu, S. F. Powell, M. J. Hochmair, et al., “Pemetrexed plus Platinum with or without Pembrolizumab in Patients with Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-specified Final Analysis from KEYNOTE-189,” Annals of Oncology 32, no. 7 (2021): 881-895.

[8] L. Paz-Ares, A. Luft, D. Vicente, et al., “Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer,” New England Journal of Medicine 379, no. 21 (2018): 2040-2051.

[9] H. West, M. McCleod, M. Hussein, et al., “Atezolizumab in Combination with Carboplatin plus Nab-paclitaxel Chemotherapy Compared with Chemotherapy Alone as First-line Treatment for Metastatic Non-squamous Non-small-cell Lung Cancer (IMpower130): A Multicentre, Randomised, Open-label, Phase 3 Trial,” The Lancet Oncology 20, no. 7 (2019): 924-937.

[10] M. Provencio, E. Nadal, A. Insa, et al., “Neoadjuvant Chemotherapy and nivolumab in Resectable Non-small-cell Lung Cancer (NADIM): An Open-label, Multicentre, Single-arm, Phase 2 Trial,” The Lancet Oncology 21, no. 11 (2020): 1413-1422.

[11] C. A. Shu, J. F. Gainor, M. M. Awad, et al., “Neoadjuvant Atezolizumab and Chemotherapy in Patients with Resectable Non-small-cell Lung Cancer: An Open-label, Multicentre, Single-arm, Phase 2 Trial,” The Lancet Oncology 21, no. 6 (2020): 786-795.

[12] P. M. Forde, J. Spicer, S. Lu, et al., “Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer,” New England Journal of Medicine 386, no. 21 (2022): 1973-1985.

[13] J. Lei, J. Zhao, L. Gong, et al., “Neoadjuvant Camrelizumab plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients with Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial,” JAMA Oncology 9, no. 10 (2023): 1348.

[14] T. Cascone, C. H. Leung, A. Weissferdt, et al., “Neoadjuvant Chemotherapy plus Nivolumab with or without ipilimumab in Operable Non-small Cell Lung Cancer: The Phase 2 Platform NEOSTAR Trial,” Nature Medicine 29, no. 3 (2023): 593-604.

[15] T. Mitsudomi, H. Ito, M. Okada, et al., “Neoadjuvant nivolumab plus Chemotherapy in Resectable Non-small-cell Lung Cancer in Japanese Patients from <Span Style = “Font-variant:Small-caps;”>CheckMate</Span>816,” Cancer Science 115, no. 2 (2024): 540-554.

[16] J. V. Heymach, D. Harpole, T. Mitsudomi, et al., “Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer,” New England Journal of Medicine 389, no. 18 (2023): 1672-1684.

[17] M. Provencio, E. Nadal, J. L. González-Larriba, et al., “Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer,” New England Journal of Medicine 389, no. 6 (2023): 504-513.

[18] H. Wakelee, M. Liberman, T. Kato, et al., “Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer,” New England Journal of Medicine 389, no. 6 (2023): 491-503.

[19] L. Wu, W. Zhang, P. Zhang, et al., “Perioperative Toripalimab + Platinum-doublet Chemotherapy vs Chemotherapy in Resectable Stage II/III Non-small Cell Lung Cancer (NSCLC): Interim Event-free Survival (EFS) Analysis of the Phase III Neotorch Study,” JCO (2023).

[20] R. U. Osarogiagbon, N. R. Faris, W. Stevens, et al., “Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization,” Journal of Thoracic Oncology 15, no. 3 (2020): 371-382.

[21] N. A. Rizvi, M. D. Hellmann, A. Snyder, et al., “Cancer Immunology. Mutational Landscape Determines Sensitivity to PD-1 Blockade in Non-small Cell Lung Cancer,” Science (New York, NY) 348, no. 6230 (2015): 124-128.

[22] L. Galluzzi, E. Vacchelli, J.-M. Bravo-San Pedro, et al., “Classification of Current Anticancer Immunotherapies,” Oncotarget 5, no. 24 (2014): 12472-12508.

[23] L. Galluzzi, J. Humeau, A. Buqué, L. Zitvogel, and G. Kroemer, “Immunostimulation with Chemotherapy in the Era of Immune Checkpoint Inhibitors,” Nature Reviews Clinical Oncology 17, no. 12 (2020): 725-741.

[24] G. Guyatt, A. D. Oxman, E. A. Akl, et al., “GRADE Guidelines: 1. Introduction-GRADE Evidence Profiles and Summary of Findings Tables,” Journal of Clinical Epidemiology 64, no. 4 (2011): 383-394.

[25] J. P. A. Ioannidis, “Integration of Evidence from Multiple Meta-analyses: A Primer on Umbrella Reviews, Treatment Networks and Multiple Treatments Meta-analyses,” CMAJ: Canadian Medical Association Journal 181, no. 8 (2009): 488-493.

[26] N. Veronese, M. Solmi, M. G. Caruso, et al., “Dietary fiber and Health Outcomes: An Umbrella Review of Systematic Reviews and Meta-analyses,” American Journal of Clinical Nutrition 107, no. 3 (2018): 436-444.

[27] T. C. Wallace, R. L. Bailey, J. B. Blumberg, et al., “Fruits, Vegetables, and Health: A Comprehensive Narrative, Umbrella Review of the Science and Recommendations for Enhanced Public Policy to Improve Intake,” Critical Reviews in Food Science and Nutrition 60, no. 13 (2020): 2174-2211.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.